Search results for "Delayed-Action Preparation"

showing 10 items of 101 documents

Finely Tuned Temperature-Controlled Cargo Release Using Paraffin-Capped Mesoporous Silica Nanoparticles

2011

[EN] Trapped: Mesoporous silica nanoparticles were loaded with a fluorescent guest and functionalized with octadecyltrimethoxysilane. The alkyl chains interact with paraffins, which build a hydrophobic layer around the particle (see picture). Upon melting of the paraffin, the guest molecule is released, as demonstrated in cells for the guest doxorubicin. The release temperature can be tuned by choosing an appropriate paraffin. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Models MolecularINGENIERIA DE LA CONSTRUCCIONGuest moleculesParaffinsParaffin waxesNanoparticlemesoporous materialsMCM-41Phenazine derivativeFunctionalizedCell survivalNanoparticleQUIMICA ORGANICAChemical structureX-Ray DiffractionSafranin tSilicon dioxideControlled releaseAlkyl chainDrug CarriersMicroscopy ConfocalMolecular StructureOctadecyltrimethoxysilaneSurface propertyTemperatureSilicaGeneral MedicineChemistryAntineoplastic agentParaffinHeLa cellPorosityHumanMaterials scienceDrug carrierX ray diffractionSurface PropertiesMesoporous silica nanoparticlesNanotechnologyAntineoplastic AgentsMesoporousCatalysisDrug interactionsArticleMicroscopy Electron TransmissionHumansCell survivalDrug effectDelayed release formulationHydrophobic layersQUIMICA INORGANICAGeneral ChemistryMesoporous silicaMolecular gatesMesoporous materialsMcm 41Confocal microscopyDrug effectSolubilityDoxorubicinDelayed-Action Preparationsdrug deliveryDrug deliveryNanoparticlesPhenazinesnanoparticlesMesoporous materialcontrolled releasemolecular gatesTransmission electron microscopyHeLa CellsAngewandte Chemie
researchProduct

A NANOPARTICULATE DRUG-DELIVERY SYSTEM FOR RIVASTIGMINE: PHYSICO-CHEMICAL AND IN VITRO BIOLOGICAL CHARACTERIZATION

2007

The preparation and characterization of surface-PE Gylated polymeric nanoparticles are described. These systems were obtained by UV irradiation of PHM and PHM-PEG(2000) as an inverse microemulsion, using an aqueous solution of the PHM/PHM-PEG(2000) copolymer mixture as the internal phase and triacetin saturated with water as the external phase, and characterized by dimensional analysis, zeta-potential measurements and XPS. in vitro biological tests demonstrated their cell compatibility and their ability to escape from phagocytosis. Rivastigmine was encapsulated into the nanoparticle structure and drug-release profiles from loaded samples were investigated in PBS at pH = 7.4 and human plasma.

Molecular StructureCell SurvivalUltraviolet RaysPhenylcarbamatesRivastigmineHemolysisPolyethylene GlycolsPOLYMERIC NANOPARTICLES RIVASTIGMINE DRUG DELIVERYDrug Delivery SystemsPolymethacrylic AcidsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoCell Line TumorDelayed-Action PreparationsHumansNanoparticlesPeptidesTriacetin
researchProduct

Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects.

2013

Naltrexone is widely used in the treatment of opiate addiction but its current peroral administration is characterized by low bioavailability with various side effects. The development of a long-acting transbuccal delivery device (IntelliDrug) for NLX may be useful to improve patient compliance and the therapy effectiveness. The aims of the study are (a) to test basic safety and effectiveness of controlled transbuccal drug delivery on human subjects; (b) to compare NLX bioavailability following transbuccal delivery vs per os conventional delivery; and (c) to test the hypothesis that transbuccal delivery is more efficient than the conventional route. In this randomized cross-over pilot study…

Naltrexone HydrochlorideAdultMaleAdolescentNarcotic AntagonistsPharmaceutical ScienceAddictionBiological AvailabilityPharmacologySmoking cessationNaltrexonelaw.inventionTransbuccal drug deliveryYoung AdultDrug Delivery SystemsRandomized controlled triallawmedicineHumansNaltrexone hydrochlorideNLXCross-Over Studiesbusiness.industryAdministration BuccalTransmucosal deliveryBuccal administrationMiddle AgedCrossover studyNaltrexoneBioavailabilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAnesthesiaDelayed-Action PreparationsDrug deliveryMouth ProtectorsFemalebusinessmedicine.drugInternational journal of pharmaceutics
researchProduct

Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids

2013

Objectives: The aim of this exploratory study was to assess the conversion ratios between tapentadol and other opioids in patients requiring an opioid switching. Methods: A prospective study was carried out in a convenience sample of consecutive patients admitted to an acute palliative care unit and a home care unit for a period of 1 year. Patients who were switched from/to tapentadol were selected. The initial ratio between tapentadol and other opioids, expressed as oral morphine equivalents was 1:3.3. The subsequent doses were flexible and were changed to fit the patients’ needs. Pain intensity and distress score were recorded until opioid doses were stable. In all, 37 patients were exami…

NarcoticsPalliative careReceptors Opioid muPainSettore MED/41 - AnestesiologiaOpioidPhenolsNeoplasmsReceptorsmedicineHumansIn patientProspective StudiesCancer painProspective cohort studyConversion ratioAnalgesicsMorphinebusiness.industryMedicine (all)Palliative CareCancerGeneral MedicineTapentadolmedicine.diseaseAnalgesics OpioidTapentadolOpioidmuDelayed-Action PreparationsAnesthesiaCancer pain; Conversion ratio; Opioid switching; Tapentadol; Analgesics Opioid; Delayed-Action Preparations; Humans; Morphine; Narcotics; Neoplasms; Pain; Palliative Care; Phenols; Prospective Studies; Receptors Opioid mu; Medicine (all)Opioid switchingExtended releasebusinessCancer painCancer pain Conversion ratio Opioid switching Tapentadol Analgesiamedicine.drugCurrent Medical Research and Opinion
researchProduct

Slow release oral morphine versus methadone for the treatment of opioid use disorder

2019

ObjectiveTo assess the efficacy of slow release oral morphine (SROM) as a treatment for opioid use disorder (OUD).DesignSystematic review and meta-analysis of randomised controlled trials (RCTs).Data sourcesThree electronic databases were searched through 1 May 2018: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We also searched the following electronic registers for ongoing trials: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the EU Clinical Trials Register.Eligibility criteria for selecting studiesWe included RCTs of all durations, assessing the effect of SROM on measures of treatment retention, heroin use…

Narcoticsmedicine.medical_specialtyAddictionAdministration OralCraving1681substance use treatmentHeroin03 medical and health sciences0302 clinical medicineSlow release oral morphine (SROM)Internal medicineOpiate Substitution TreatmentHumansMedicine1506030212 general & internal medicine10. No inequalityAdverse effectRandomized Controlled Trials as TopicMorphinebusiness.industryResearchsubstance misuseopioid use disorderOpioid use disorderGeneral MedicineOpioid-Related Disordersmedicine.disease3. Good healthmeta-analysisClinical trialoral morphineOpioid use disorderReducing heroin useDelayed-Action PreparationsMeta-analysisRelative riskmedicine.symptombusinessMethadone030217 neurology & neurosurgerymedicine.drugMethadoneBMJ Open
researchProduct

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

2015

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role…

NiacinamideErythrocytesPolymers and PlasticsCell SurvivalAdamantaneDrug CompoundingSupramolecular chemistryBioengineeringNanotechnologyAdamantaneAntineoplastic AgentsBinding CompetitiveHemolysisAmphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cellsHCC cellsBiomaterialschemistry.chemical_compoundSurface-Active AgentsIn vivoCell Line TumorAmphiphileMaterials ChemistryHumanschemistry.chemical_classificationCyclodextrinsAqueous solutionCyclodextrinPhenylurea CompoundsSorafenibFluorescenceCombinatorial chemistrydigestive system diseasesNanostructuresBINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLESDrug LiberationKineticsnanoassembliecyclodextrinchemistryDelayed-Action PreparationsProton NMRHepatocytes
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of…

2004

Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring…

Pathophysiology of asthmamedicine.drug_classInflammationAdrenal Cortex HormonesBronchodilatorAdministration InhalationmedicineHumansPharmacology (medical)Adrenergic beta-2 Receptor AgonistsAsthmaLungmedicine.diagnostic_testLeukotriene receptorbusiness.industryNebulizers and Vaporizersmedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavageDelayed-Action PreparationsImmunologyLeukotriene AntagonistsBronchoconstrictionDrug Therapy CombinationReceptors Adrenergic beta-2medicine.symptombusinessDrugs
researchProduct

Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant D…

2020

OBJECTIVE To assess the efficacy of the non-stimulant guanfacine extended release (GXR) on attention-deficit/hyperactivity disorder (ADHD) symptoms in children and adolescents, with and without comorbid oppositional defiant disorder (ODD). METHODS Data were derived from 4 phase 3, randomized, placebo-controlled trials of dose-optimized GXR monotherapy, in which at least 10% of participants had a diagnosis of comorbid ODD. SPD503-312 and SPD503-316 were 10- to 13-week studies of GXR (1-7 mg/d). SPD503-314 and SPD503-307 were 8-week studies of GXR (1-4 mg/d). Efficacy was assessed using the ADHD Rating Scale IV (ADHD-RS-IV) total scores. RESULTS In total, 1,084 participants were included (SPD…

Pediatricsmedicine.medical_specialtyAdolescentDouble-Blind MethodRating scalemental disordersAdrenergic alpha-2 Receptor AgonistsDevelopmental and Educational PsychologymedicineHumansAttention deficit hyperactivity disorderPooled dataChildPsychiatric Status Rating ScalesDose-Response Relationship Drugbusiness.industrymedicine.diseaseConfidence intervalGuanfacineGuanfacinePsychiatry and Mental healthTreatment OutcomeAttention Deficit Disorder with HyperactivityAttention Deficit and Disruptive Behavior DisordersDelayed-Action PreparationsOppositional defiantPediatrics Perinatology and Child HealthCore symptomsExtended releasebusinessmedicine.drugJournal of Developmental & Behavioral Pediatrics
researchProduct

Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol® ATO 5

2005

Abstract Lipid excipients are usually used for the development of sustained-release formulations. When used in relatively high quantities, Precirol ® ATO 5 imparts sustained-release properties to solid oral dosage forms, by forming a lipid matrix. To control or adjust the drug release kinetics from such lipid matrix however, one must often resort to complementary ingredients or techniques. This study investigates the influence of poloxamers (Lutrol ® ) included in lipid matrices composed of glyceryl palmitostearate (Precirol ® ATO 5) on their dissolution performance and their stability. The addition of these hydrophilic polymers in the lipid matrix increased the amount of theophylline relea…

Pharmaceutical ScienceExcipientPoloxamerMolding (process)In Vitro TechniquesDosage formDiglyceridesExcipientsDrug StabilityTheophyllinemedicineTechnology PharmaceuticalTheophyllineDissolutionChromatographyCalorimetry Differential ScanningViscosityChemistryWaterPoloxamerControlled releaseKineticsMicroscopy ElectronModels ChemicalSolubilityDelayed-Action PreparationsSwellingmedicine.symptomRheologyPorositymedicine.drugInternational Journal of Pharmaceutics
researchProduct